Stocks and Investing
Stocks and Investing
Tue, August 16, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, August 15, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Raghuram Selvaraju Maintained (SPRO) at Strong Buy with Decreased Target to $7 on, Aug 15th, 2022
Raghuram Selvaraju of HC Wainwright & Co., Maintained "Spero Therapeutics, Inc." (SPRO) at Strong Buy with Decreased Target from $10 to $7 on, Aug 15th, 2022.
Raghuram has made no other calls on SPRO in the last 4 months.
There are 4 other peers that have a rating on SPRO. Out of the 4 peers that are also analyzing SPRO, 3 agree with Raghuram's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Esther Hong of "Berenberg" Downgraded from Strong Buy to Hold and Held Target at $2 on, Friday, May 20th, 2022
- Ritu Baral of "Cowen & Co." Downgraded from Buy to Hold on, Wednesday, May 4th, 2022
- Josh Schimmer of "Evercore ISI Group" Downgraded from Buy to Hold and Decreased Target to $2 on, Wednesday, May 4th, 2022
This is the rating of the analyst that currently disagrees with Raghuram
- Louise Chen of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $5 on, Tuesday, May 17th, 2022
Contributing Sources